Final results from a phase II study of infigratinib (BGJ398), an FGFR ...
2021年1月22日 · Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma …
Infigratinib (Synonyms: BGJ-398; NVP-BGJ398) - MCE-生物活性 …
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC50 s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Infigratinib …
Infigratinib (BGJ398) in previously treated patients with …
2021年8月3日 · Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally …
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced ...
2018年1月20日 · Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective …
国内上市在即！Infigratinib获FGFR2扩增胃癌突破性疗法认定
2023年6月20日 · Infigratinib是一种口服的、ATP竞争性的成纤维细胞生长因子受体酪氨酸激酶抑制剂（TKI），靶向纤维细胞生长因子受体（FGFR）蛋白，阻断下游活性。 Infigratinib. 在临床 …
胆管癌靶向药：英菲格拉替尼_Infigratinib - 知乎
nfigratinib（BGJ398）是一种口服给药的选择性成纤维细胞生长因子受体（FGFR）酪氨酸激酶抑制剂，2020年1月初被FDA授予快速通道资格。 II期研究发现， 既往化疗失败、FGFR2融合的 …
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 …
2017年1月10日 · Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant …
Infigratinib (BGJ398) in previously treated patients with advanced …
Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic …
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 …
2016年11月21日 · BGJ398, an orally bioavailable, selective FGFR1 to 3 inhibitor (half maximal inhibitory concentration values range from 0.9 to 1.4 nM for FGFR1-3 to 60 nM for FGFR4), 19 …
【JCO】FGFR融合型胆囊癌靶向治疗新希望——BGJ398 - 网易
2017年12月3日 · bgj398是一个口服的、选择性泛fgfr激酶抑制剂，在动物实验中显示出较好的活性。在早期的临床试验中，bgj398显示出较好的安全性和抗肿瘤活性，常见的副作用包括高磷血 …